Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug

This article was originally published here

Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at

The post Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply